Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02833610 · ClinicalTrials.gov registry record · Phase 2
A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT02833610: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT02833610 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02833610, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
This research study is studying a possible therapy as a possible treatment for the consequences of Multiple Myeloma with renal insufficiency.
Interventions
- DRUG Denosumab Q4W
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2016-08 |
| Est. Completion | 2023-03-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02833610
The ClinicalTrials.gov registry entry for NCT02833610 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Denosumab Q4W is the first listed.
NCT02833610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02833610 about?
NCT02833610 is a clinical study titled "A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency". This research study is studying a possible therapy as a possible treatment for the consequences of Multiple Myeloma with renal insufficiency.
What is the current status of trial NCT02833610?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2016-08. Estimated completion is 2023-03-20.
What interventions are being tested in trial NCT02833610?
The interventions under investigation include: Denosumab Q4W (DRUG).
Who is sponsoring clinical trial NCT02833610?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.